

# A comparative study of the efficacy and tolerance of three antiglaucoma prostaglandin analogue eyedrops (Latanoprost, Travoprost and Bimatoprost)

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 17/02/2011	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Mr Usama Faridi

### Contact details

Ophthalmology Department  
Taunton and Somerset Hospital  
Musgrove Park  
Taunton  
United Kingdom  
TA1 5DA  
+44 (0)1823 342122  
[usama.faridi@tst.nhs.uk](mailto:usama.faridi@tst.nhs.uk)

## Additional identifiers

### Protocol serial number

N0249122172

## Study information

## **Scientific Title**

### **Study objectives**

What is the relative efficacy and tolerance of three prostaglandin analogue eyedrops?

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Informed consent was obtained from all patients. The study was approved by the local Research Ethics Committee (Somerset Research Ethics Committee) and the Medicines and Healthcare products Regulatory Agency, UK and was run in accordance with the principles of Good Clinical Practice (Helsinki declaration).

### **Study design**

Randomised controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Not Specified

### **Health condition(s) or problem(s) studied**

Eye Diseases: Glaucoma

### **Interventions**

1. Latanoprost
2. Travoprost
3. Bimatoprost

### **Intervention Type**

Drug

### **Phase**

Not Specified

### **Drug/device/biological/vaccine name(s)**

prostaglandin: Latanoprost, Travoprost, Bimatoprost

### **Primary outcome(s)**

Added March 2008:

A comparison of the efficacy, in terms of intra-ocular pressure reduction.

### **Key secondary outcome(s)**

Added March 2008:

A comparison of the tolerance profile.

### **Completion date**

31/10/2006

## Eligibility

### Key inclusion criteria

Added March 2008:

Newly diagnosed patients with ocular hypertension, open angle glaucoma (including primary open angle glaucoma, pseudo-exfoliation and pigment dispersion syndrome) or normal tension glaucoma.

### Participant type(s)

Patient

### Healthy volunteers allowed

No

### Age group

Not Specified

### Sex

Not Specified

### Key exclusion criteria

Added March 2008:

1. Patients <20 years
2. Pregnancy
3. Intraocular pressure (IOP) of 40 mmHg or more
4. Severe visual field loss or scotoma within 5° of fixation
5. Patients with secondary glaucoma
5. History of intraocular surgery in the preceding year
6. Prostaglandin derivative was contraindicated

### Date of first enrolment

01/02/2003

### Date of final enrolment

31/10/2006

## Locations

### Countries of recruitment

United Kingdom

England

### Study participating centre

Ophthalmology Department

Taunton

United Kingdom  
TA1 5DA

## Sponsor information

**Organisation**  
Department of Health (UK)

## Funder(s)

**Funder type**  
Government

**Funder Name**  
Taunton and Somerset NHS Trust (UK)

## Results and Publications

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2010		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes